Strande JL, Kurra V, Jeswani R, Oberoi R, Sharpsten L, Neutel J, et al
These opposite ends of the spectrum are at least a decade apart
Glucagon-like peptide-1: new regulator in lipid metabolism
ABBREVIATIONS AND ACRONYMS CKD chronic kidney disease CVD cardiovascular disease CVOT cardiovascular outcome trials DPP4i dipeptidyl peptidase 4 inhibitors GLP1RA glucagon-like peptide 1 receptor antagonist HbA1c hemoglobin A1c HF heart failure MI myocardial infarction SGLT2i sodium glucose transporter 2 inhibitor T2DM type 2 diabetes mellitus TZD thiazolidinediones REFERENCES 1.Di Angelantonio E, Kaptoge S, Wormser D, et al
MK-677 requires careful evaluation in women because it may increase appetite and water retention
The event is a comprehensive one-day program to motivate individuals with diabetes to put Diabetes In Motion to manage their disease more effectively with physical activity